Global Apheresis Equipments Market Analysis

The Global Apheresis Equipments Market size stood at around xx Bn in 2023 and is projected to reach US $xx Bn by 2033, exhibiting a CAGR of xx% during the forecast period.

The Global Apheresis Equipments Market Executive Summary

Apheresis is a procedure that enables healthcare providers to obtain or remove red blood cells, white blood cells, platelets and plasma for medical treatment. It’s also known as pheresis or hemapheresis. In apheresis, a centrifuge machine draws blood from your body and spins the blood to separate its elements. The machine sets aside certain elements and returns the remaining blood cells, platelets and plasma to your body.

The apheresis equipment market is expanding due to rising chronic diseases, technological advancements, and growing awareness of blood donation. Key drivers include the increasing need for blood components and improvements in apheresis technology. However, high costs and regulatory challenges may hinder growth. The market is segmented by product type, application, and end-user, with North America and Europe leading, while Asia-Pacific is expected to experience significant growth. Major players in the market include Terumo BCT, Fresenius Kabi, and Haemonetics Corporation. Overall, the market is set for growth with continued technological innovations and increased healthcare investments.    

Global Apheresis Equipments Market Dynamics

Market Growth Drivers

As chronic diseases continue rising, so does the need for apheresis- a treatment that separates and eliminates specific unhealthy components in the bloodstream. There has been significant progress in technology regarding apheresis equipment, making the instruments safe and efficient. The demand for blood components has also risen as there is a growing awareness of blood disorders in developed regions, and the availability of favourable reimbursement policies. Furthermore, the development of healthcare facilities in the growth horns such as emerging markets also aid in increasing the usage of apheresis equipment. 

Opportunity

Further development of apheresis equipment includes, new applications in regenerative medicine and gene therapies, looking at AI, ML, and IoT for improving apheresis equipment, cost-effective and portable machines to make them more accessible. Alliances and partnerships are also known to influence innovation and market advancement. 

Market Restraints

High initial cost of capital which is likely to lead to low uptake and create budget constrains especially among the developing countries. Tough regulatory standards are often a hindrance to the fast approval of products and the integration of new technologies into the market. One of the challenges that can impede market adoption is a lack of qualified personnel able to operate apheresis equipment. 

Competitive Landscape for Apheresis Equipments Market in Global

Key Players

• Fresenius Kabi AG
• Terumo Corporation
• B. Braun Melsungen AG
• Haemonetics Corporation
• Asahi Kasei Medical Co., Ltd.
• Terumo BCT, Inc.

Recent Developments

September 2023, Sanguine Biosciences (Sanguine), a leader in connecting patients with biomedical researchers to accelerate precision medicine R&D, this week announced its opening of a blood donor centre in Los Angeles. The centre will specialize in collecting concentrated white blood cell biospecimens through apheresis from participants in Sanguine’s Patient Community network.

June 2022, NHS England Chooses Spectra Optia® Apheresis System as Part of MedTech Funding Mandate for Expansion of Sickle Cell Disease Treatment. Adoption of Terumo Blood and Cell Technologies’ Spectra Optia will Save the UK’s NHS an Expected GBP 13 Million per Year.

Healthcare Policies and Regulatory Landscape for Apheresis Equipments Market in Global

Policy changes and Reimbursement scenario

Policies within the healthcare sector focusing on better technologies in medicine, as well as the management of chronic diseases, will exercise positive influence on apheresis equipment adoption. Less restrictive FDA regulations and increased emphasis on chronic diseases can drive market expansion. Hypothenar access, especially in areas such as North America, increases the utilization of apheresis procedures; however, inconsistencies in reimbursement practices around the world may affect adoption. Emerging markets have potential for better reimbursement conditions and availability of apheresis treatments when healthcare systems and related infrastructure evolve.